The prescribing pattern of paliperidone in a pediatric population

References

• Clarke WP, Chavera TA, Silva M, et al. Signalling profile differences: paliperidone versus risperidone. Br J Pharmacol. 2013;170(3):532–545. doi: 10.1111/bph.12295
   PubMed Web of Science ®Google Scholar
• Bymaster FP, Felder CC, Tzavara E, et al. Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1125–1143. doi: 10.1016/j.pnpbp.2003.09.008
   PubMed Web of Science ®Google Scholar
• Kantrowitz J, Citrome L. Paliperidone: the evidence of its therapeutic value in schizophrenia. Core Evid. 2008;2(4):261–271.
   PubMedGoogle Scholar
• Greenberg WM, Citrome L. Paliperidone palmitate for schizoaffective disorder: a review of the clinical evidence. Neurol Ther. 2015;4:81–91. doi: 10.1007/s40120-015-0030-4
   PubMed Web of Science ®Google Scholar
• Savitz AJ, Lane R, Nuamah I, et al. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. J Am Acad Child Adolesc Psychiatry. 2015;54(2):126–137. doi: 10.1016/j.jaac.2014.11.009
   PubMed Web of Science ®Google Scholar
• Fernández-Mayoralas DM, Fernández-Jaén A, Muñoz-Jareño N, et al. Treatment with paliperidone in children with behavior disorders previously treated with risperidone: an open-label trial. Clin Neuropharmacol. 2012;35(5):227–230. doi: 10.1097/WNF.0b013e31826818cd
   Web of Science ®Google Scholar
• Joshi G1, Petty C, Wozniak J, et al. A prospective open-label trial of paliperidone monotherapy for the treatment of bipolar spectrum disorders in children and adolescents. Psychopharmacology (Berl.). 2013;227(3):449–458. doi: 10.1007/s00213-013-2970-7
   PubMed Web of Science ®Google Scholar
• Stigler KA, Erickson CA, Mullett JE. Paliperidone for irritability in autistic disorder. J Child Adolesc Psychopharmacol. 2010;20(1):75–78. doi: 10.1089/cap.2009.0019
   PubMed Web of Science ®Google Scholar
• Stigler KA, Mullett JE, Erickson CA, et al. Paliperidone for irritability in adolescents and young adults with autistic disorder. Psychopharmacology (Berl.). 2012;223(2):237–45. doi: 10.1007/s00213-012-2711-3
   PubMed Web of Science ®Google Scholar
• Seida JC, Schouten JR, Boylan K, et al. Antipsychotics for children and young adults: a comparative effectiveness review. Pediatrics. 2012;129:771–784. doi: 10.1542/peds.2011-2158
   PubMed Web of Science ®Google Scholar
• Dilbaz N, Darçın AE. Antipsikotik İlaçlarla Tedavide Yeni Bir Teknoloji; Paliperidon. A novel technology in treatment with antipsychotic drugs; paliperidone. Bulletin of Clinical Psychopharmacology. 2009;19(2):316–325.
   Google Scholar
• Cooper WO, Arbogast PG, Ding H, et al. Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr. 2006;6(2):79–83. doi: 10.1016/j.ambp.2005.11.002
   PubMedGoogle Scholar
• Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20(2):177–84. doi: 10.1002/pds.2082
   PubMed Web of Science ®Google Scholar
• Sohn M, Moga DC, Blumenschein K, et al. National trends in off-label use of atypical antipsychotics in children and adolescents in the United States. Medicine. 2014;95(23):e3784. doi: 10.1097/MD.0000000000003784
   Web of Science ®Google Scholar
• Maglione M, Maher AR, Hu J, et al. Off-label use of atypical antipsychotics: an update [Internet]. AHRQ Comparative Effectiveness Reviews. 2011;43.
   Google Scholar
• Pathak P, West D, Martin BC, et al. Evidence-based use of second-generation antipsychotics in a state medicaid pediatric population, 2001-2005. Psychiatr Serv. 2010;61(2):123–29. doi: 10.1176/ps.2010.61.2.123
   PubMed Web of Science ®Google Scholar
• Rettew DC, Greenblatt J, Kamon J, et al. Antipsychotic medication prescribing in children enrolled in medicaid pediatrics. Pediatrics. 2015;135:658.
   Google Scholar
• Citrome L, Kalsekar I, Guo Z, et al. Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis. Clin Ther. 2013;35(12):1867–1875. doi: 10.1016/j.clinthera.2013.09.006
   PubMed Web of Science ®Google Scholar
• Olfson M, Blanco C, Wang S, et al. National trends in the mental health care of children, adolescents, and adults by officebased physicians. JAMA Psychiatry. 2014;71:81–90. doi: 10.1001/jamapsychiatry.2013.3074
   PubMed Web of Science ®Google Scholar
• Tramontina S, Zeni CP, Ketzer CR, et al. Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: a pilot randomized clinical trial. J Clin Psychiatry. 2009;70(5):756–764. doi: 10.4088/JCP.08m04726
   PubMed Web of Science ®Google Scholar
• Knapp P, Chait A, Pappadopulos E, et al. Treatment of maladaptive aggression in youth: CERT guidelines I. Engagement, assessment, and management. Pediatrics. 2012;129:1562–1576. doi: 10.1542/peds.2010-1360
   PubMed Web of Science ®Google Scholar
• Scotto Rosato N, Correll CU, Pappadopulos E, et al. Treatment of maladaptive aggression in youth: CERT guidelines II. Treatments and ongoing management. Pediatrics 2012;129:1577–1586. doi: 10.1542/peds.2010-1361
   PubMed Web of Science ®Google Scholar
• Armenteros JL, Lewis JE, Davalos M. Risperidone augmentation for treatment-resistant aggression in attention deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry. 2007;46(5):558–65. doi: 10.1097/chi.0b013e3180323354
   PubMed Web of Science ®Google Scholar
• Menard M, Thummler S, Giannitelli M, et al. Incidence of adverse events in antipsychotic-naive children and adolescents treated with antipsychotic drugs: a French multicentre naturalistic study protocol (ETAPE). BMJ Open. 2016;6:11–20. doi: 10.1136/bmjopen-2015-011020
   Web of Science ®Google Scholar
• Leslie DL, Rosenheck R. Off-label use of antipsychotic medications in medicaid. Am J Manag Care. 2012;18(3):109–117.
   Web of Science ®Google Scholar
• Weiss M, Panagiotopoulos C, Giles L, et al. A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic. J Child Adolesc Psychopharmacol. 2009;19(5):575–582. doi: 10.1089/cap.2009.0050
   PubMed Web of Science ®Google Scholar
• Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry. 2005;66(Suppl 7):29–40.
   PubMedGoogle Scholar
• Correia Filho AG, Bodanese R, Silva TL, et al. Comparison of risperidone and methylphenidate for reducing ADHD symptoms in children and adolescents with moderate mental retardation. J Am Acad Child Adolesc Psychiatry. 2005;44(8):748–55. doi: 10.1097/01.chi.0000166986.30592.67
   PubMed Web of Science ®Google Scholar
• Kutcher S, Aman M, Brooks SJ, et al. International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol. 2004;14(1):11–28. doi: 10.1016/S0924-977X(03)00045-2
   PubMed Web of Science ®Google Scholar
• Smarty S, Findling RL. Psychopharmacology of pediatric bipolar disorder: a review. Psychopharmacology. 2007;191:39–54. doi: 10.1007/s00213-006-0569-y
   PubMed Web of Science ®Google Scholar
• McClellan J, Kowatch R, Findling RL. Work group on quality issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:107–125. doi: 10.1097/01.chi.0000242240.69678.c4
   PubMed Web of Science ®Google Scholar
• Oh J, Chang JG, Lee SB, et al. Comparison of aripiprazole and other atypical antipsychotics for pediatric bipolar disorder: a retrospective chart review of efficacy and tolerability. Clin Psychopharmacol Neurosci. 2013;11(2):72–79. doi: 10.9758/cpn.2013.11.2.72
   Web of Science ®Google Scholar
• Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2006;67:509–516. doi: 10.4088/JCP.v67n0401
   PubMed Web of Science ®Google Scholar
• Barzman DH, DelBello MP, Kowatch RA, et al. The effectiveness and tolerability of aripiprazole for pediatric bipolar disorders: a retrospective chart review. J Child Adolesc Psychopharmacol. 2004;14:593–600. doi: 10.1089/cap.2004.14.593
   PubMed Web of Science ®Google Scholar
• Joshi G, Petty C, Wozniak J, et al. A prospective open-label trial of quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder. J Affect Disord. 2012;136:1143–1153. doi: 10.1016/j.jad.2011.09.042
   Web of Science ®Google Scholar
• Findling RL, McKenna K, Earley WR, et al. Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial. J Child Adolesc Psychopharmacol. 2012;22(5):327–342. doi: 10.1089/cap.2011.0092
   PubMed Web of Science ®Google Scholar
• Marino J, English C, Caballero J, et al. The role of paliperidone extended release for the treatment of bipolar disorder. Neuropsychiatr Dis Treat. 2012;8:181–189.
   Web of Science ®Google Scholar
• Joshi G, Petty C, Wozniak J, et al. A prospective open-label trial of paliperidone monotherapy for the treatment of bipolar spectrum disorders in children and adolescents. Psychopharmacology (Berl.). 2013;227(3);449–458. doi: 10.1007/s00213-013-2970-7
   PubMed Web of Science ®Google Scholar